A register study explored the worldwide collected data on MACEs and venous thromboembolism associated with JAK inhibitors compared to anti-TNF agents in RA.
A study with inflammatory bowel disease (IBD) patients revealed an 8.7% prevalence of fibromyalgia, which is higher than the prevalence in the general population (2–3%).
A post-hoc analysis of the SENSCIS trial revealed that nintedanib treatment benefit is evident in patients with 4 characteristics associated with a fast decline in lung function.
A large register study in Denmark detected a substantially higher mortality risk for patients with rheumatoid arthritis (RA) who had comorbid depression.
Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial.
Data from a cohort study detected various factors that were linked to a risk amplification for the development of dementia in patients with rheumatoid arthritis (RA).
A study revealed that osteoarthritis is associated with a wide variety of diseases previously thought to be unrelated, such as anaemia and thromboembolic disease.
During the double-blind period of a withdrawal trial, baricitinib demonstrated predominance over placebo in the prevention of disease flares.
In both psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), a T2T TNF-blocker tapering strategy showed to be non-inferior to a T2T strategy.
Once-daily therapy with upadacitinib led to an ASAS40 response in 45% of patients with active nr-axSpA at week 14 in the SELECT-AXIS-2 trial.
esanum talks with Prof. Brunetti about AI in medicine, its ethical implications and physicians' approach to this tech revolution.
New technologies have transformed haematology almost completely. Gene-editing and small molecular agents become available to patients without greater delays.
esanum talks with Prof. Bonini about her research projects, her EHA board role and the prospects for young hematologists who wish to engage in research.
Trial results show equal DA-EPOCH-R efficacy to CODOX-M/R-IVAX as first-line treatment in patients, but less toxicity.
Leniolisib is safe, increases naïve B cells, decreases lymphadenopathy and spleen size, and improves cytopenia in APDS/PASLI.
Early ASCT in lenalidomide / bortezomib / dexamethasone therapy followed by lenalidomide maintenance, significantly improves PFS for newly diagnosed MM
Exa-cel gene-editing therapy is associated with increase in foetal and total haemoglobin in transfusion-dependent β-thalassemia or severe sickle cell disease patients.
Phase-3 trial shows improved PFS with venetoclax/obinutuzumab/ibrutinib therapy in fit, untreated patients with chronic lymphocytic leukaemia.
A new platform connects the spheres of medical care and health innovation. It allows caregivers to find assignments with innovation actors, including companies.
CPX-351 does not improve response, overall survival, or event-free survival compared with FLAG-Ida in AML patients with adverse cytogenetics.